# Evaluation of RealStar®Alpha Herpesvirus PCR Kit for Detection of HSV-1, HSV-2, and VZV in Clinical Specimens

Authors: Cyril C. Y. Yip; Siddharth Sridhar; Kit-Hang Leung; Andrew K. W. Cheng; Kwok-Hung Chan; Jasper F. W. Chan; Vincent C. C. Cheng; Kwok-Yung Yuen
Journal: BioMed Research International
 (2019)

---

## Abstract

Several commercial PCR kits are available for detection of herpes simplex virus (HSV) and varicella zoster virus (VZV), but the test performance of one CE-marked in vitro diagnostic kit—RealStar®alpha Herpesvirus PCR Kit—has not been well studied. This study evaluated the performance of RealStar® alpha Herpesvirus PCR Kit 1.0 on the LightCycler® 480 Instrument II for detection and differentiation of HSV-1, HSV-2, and VZV in human clinical specimens. We evaluated the analytical sensitivity of the RealStar® and in-house multiplex real-time PCR assays using serial dilutions of nucleic acids extracted from clinical specimens. The analytical sensitivity of the RealStar® assay was 10, 32, and 100 copies/reaction for HSV-1, HSV-2, and VZV, respectively, which was slightly higher than that of the in-house multiplex real-time PCR assay. Reproducibility of the cycle threshold (Cp) values for each viral target was satisfactory with the intra- and interassay coefficient of variation values below 5% for both assays. One-hundred and fifty-three clinical specimens and 15 proficiency testing samples were used to evaluate the diagnostic performance of RealStar® alpha Herpesvirus PCR Kit against the in-house multiplex real-time PCR assay. The RealStar® assay showed 100% sensitivity and specificity when compared to the in-house assay. Cp values of the RealStar® and in-house assays showed excellent correlation. RealStar® alpha Herpesvirus PCR is a sensitive, specific, and reliable assay for the detection of HSV-1, HSV-2, and VZV, with less extensive verification requirements compared to a laboratory developed assay.


---

## Body

## 1. Introduction

Herpes simplex virus- (HSV-) 1, HSV-2, and varicella zoster virus (VZV) are important pathogenic human herpesviruses. The manifestations of HSV-1, HSV-2, and VZV often overlap, making clinical differentiation difficult. For example, all three viruses can cause meningoencephalitis, keratoconjunctivitis, and retinitis. HSV-1 and HSV-2 both cause genital herpes, which can mimic perineal or sacral herpes zoster due to VZV [1]. Precise virological diagnosis is important as antiviral dosages and schedules for HSV-1, HSV-2, and VZV infections differ [2, 3]. Furthermore, confirming VZV infections has distinct infection control implications in healthcare settings as patients may require airborne isolation, especially in hematology or transplant wards.Cell culture and direct fluorescence-antibody assay have been used for HSV and VZV detection, but they are less sensitive when compared to molecular tests [4–6]. Performing one-stop multiplex real-time HSV and VZV PCR assay is an attractive choice for molecular virology laboratories due to convenience, speed, user satisfaction, and lower manpower requirements [7–11]. In this study, we evaluated the performance of a commercially available RealStar® alpha Herpesvirus PCR Kit 1.0 capable of detecting and differentiating HSV-1, HSV-2, and VZV against our in-house developed multiplex PCR assay using archived clinical specimens and proficiency testing samples.


## 2. Materials and Methods

### 2.1. Samples Used for Evaluation

This study included 153 clinical specimens (Table1) sent for HSV and/or VZV testing to the Microbiology Laboratory at Queen Mary Hospital in Hong Kong during March 2017 to July 2019. In addition to the clinical specimens used for assay validation, 15 samples with various concentrations of HSV/VZV or negative for HSV/VZV from College of American Pathologists (CAP) and Quality Control for Molecular Diagnostics (QCMD) were used for external quality assessment (EQA). This study was approved by the Institutional Review Board (IRB) of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. The samples analyzed had been deidentified to staff undertaking the evaluation and no clinical or demographic details were analyzed. Hence, the need for informed consent from patients was waived by the IRB.Table 1
Clinical specimens used for evaluation.
Specimen type
Number
Eye (anterior chamber aspirate, aqueous and vitreous tapping, swab, biopsy)
29
Genital swabs (penile, vaginal, vulval)
23
CSF
20
Mouth/oral swab, saliva
20
Plasma
20
Respiratory specimens
21
Others (blister fluid, lesion/skin/vesicle swabs, gastric fluid)
20
CSF, cerebrospinal fluid.


### 2.2. Viral Nucleic Acid Extraction

Samples were subjected to total nucleic acid (TNA) extraction by using the NucliSENS easyMAG extraction system (bioMérieux, France). The volume of the samples used for TNA extraction and the elution volume depended on the sample type and the amount of sample available (Table2). Aqueous/vitreous biopsy was extracted by QIAamp DNA Mini Kit (QIAGEN, Germany), with the elution volume of 200 μL, according to manufacturer’s instructions.Table 2
Samples used for TNA extraction by the NucliSENS easyMAG extraction system.
Sample type
Sample volume (μL)
Elution volume (μL)
CSF, body fluids, aqueous/vitreous tapping, anterior chamber aspirate
200/100 or ≤50
50 or 30
Plasma
1000/500
25
∗Specimens in VTM
250
55
∗Genital swabs, oral swab, skin swab, vesicle fluid/swab, and respiratory specimens. VTM, viral transport medium.


### 2.3. RealStar®Alpha Herpesvirus PCR

The samples were run in parallel with the in-house multiplex real-time PCR using the RealStar®alpha Herpesvirus PCR Kit 1.0 (altona Diagnostics GmbH, Germany), according to the manufacturer’s instructions. Briefly, PCR was performed using the kit reagents mixed with 5 μL sample template and LightCycler® 480 Instrument II (Roche, Switzerland) with the following PCR conditions: 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and 58°C for 1 min.


### 2.4. In-House Developed Multiplex Real-Time PCR

Primers and probes used for HSV-1, HSV-2, and VZV detection and monitoring PCR inhibition are shown in Table3. A 20 μL reaction mixture contained 5 μL of 4x QuantiNova Multiplex PCR Master Mix (QIAGEN, Germany), 5 μLof nuclease-free water, 400 nM of each primer, 250 nM of each probe, 1 μL of internal control plasmid DNA (1 × 103 copies/μL), and 5 μL of sample template. The in-house multiplex real-time PCR assay was performed by LightCycler® 480 Instrument II (Roche, Switzerland). The PCR conditions consisted of 1 cycle at 95°C for 2 min, followed by 50 cycles at 95°C for 5 s and 60°C for 30 s. Plasmid controls were prepared using the pCRII-TOPO vector (Invitrogen, USA) cloned with target inserts (75 bp UL30 DNA polymerase gene of HSV-1, 117 bp envelope glycoprotein G gene of HSV-2 and 67 bp ORF29 DNA binding protein gene of VZV). Each plasmid stock was diluted in AE buffer, resulting in the concentrations of 1 × 104 copies/reaction and 1 × 102 copies/reaction as high and low positive controls, respectively. To monitor PCR inhibition in the in-house multiplex PCR assay, recombinant plasmid cloned with a 113 bp insert containing EGFP region flanked by primers derived from brome mosaic virus gene sequence of known concentration was diluted in AE buffer to be used as internal control (1 × 103 copies/reaction) [12].Table 3
Primers and probes used for the in-house developed real-time multiplex PCR assay.
Target
Sequence (5′-3′)
Amplicon size
HSV-1
Forward primer
ATCGGCGAGTACTGCATACA
75 bp (UL30 DNA polymerase gene)
Reverse primer
GAGCTCCAGATGGGGCAA
Probe
HEX-ATTCCCTGCTGGTGGGCCA-IABkFQ
HSV-2
Forward primer
ACGCTCTCGTAAATGCTTCC
117 bp (envelope glycoprotein G gene)
Reverse primer
CCACCTCTACCCACAACAGA
Probe
LC610-CGCGGAGACATTCGAGTACCAGATCG-BBQ
VZV
Forward primer
CGAGAACGGTTTGGGTTT
67 bp (ORF29 DNA binding protein gene)
Reverse primer
CGCCGGTCGTCTCAACAG
Probe
FAM-CGCTGCCAAGGGCCTCCTGTT-IABkFQ
Internal control
Forward primer
GTTCACCGATAGACCGCTG
113 bp
Reverse primer
AAGAGCCCGGAATGTCAAGA
Probe
Cy5-ACTACCTGAGCACCCAGTCCGCCCT-BBQ


### 2.5. Analytical Sensitivity, Specificity, and Imprecision

Analytical sensitivity (limit of detection) was determined by evaluating a dilution series of TNA extracted from clinical specimens containing HSV-1 or HSV-2 or VZV. Ten-fold serial dilutions of each recombinant plasmid (HSV-1/HSV-2/VZV) were used to generate standard curves for measuring DNA concentration of original extracts of each virus. Each concentration was tested in 8 replicates for both RealStar® and in-house multiplex real-time PCR assays. Probit analysis was used to calculate the limit of detection (LOD) of the assays. Analytical specificity (cross reactivity) was determined by testing a panel of genomic DNA/RNA extracted from other herpesviruses or other pathogens significant in immunocompromised patients. Imprecision was evaluated by testing different concentrations of TNA extracted from clinical specimens containing each type of virus (in triplicate for each concentration in each run) in two independent runs.


## 2.1. Samples Used for Evaluation

This study included 153 clinical specimens (Table1) sent for HSV and/or VZV testing to the Microbiology Laboratory at Queen Mary Hospital in Hong Kong during March 2017 to July 2019. In addition to the clinical specimens used for assay validation, 15 samples with various concentrations of HSV/VZV or negative for HSV/VZV from College of American Pathologists (CAP) and Quality Control for Molecular Diagnostics (QCMD) were used for external quality assessment (EQA). This study was approved by the Institutional Review Board (IRB) of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. The samples analyzed had been deidentified to staff undertaking the evaluation and no clinical or demographic details were analyzed. Hence, the need for informed consent from patients was waived by the IRB.Table 1
Clinical specimens used for evaluation.
Specimen type
Number
Eye (anterior chamber aspirate, aqueous and vitreous tapping, swab, biopsy)
29
Genital swabs (penile, vaginal, vulval)
23
CSF
20
Mouth/oral swab, saliva
20
Plasma
20
Respiratory specimens
21
Others (blister fluid, lesion/skin/vesicle swabs, gastric fluid)
20
CSF, cerebrospinal fluid.


## 2.2. Viral Nucleic Acid Extraction

Samples were subjected to total nucleic acid (TNA) extraction by using the NucliSENS easyMAG extraction system (bioMérieux, France). The volume of the samples used for TNA extraction and the elution volume depended on the sample type and the amount of sample available (Table2). Aqueous/vitreous biopsy was extracted by QIAamp DNA Mini Kit (QIAGEN, Germany), with the elution volume of 200 μL, according to manufacturer’s instructions.Table 2
Samples used for TNA extraction by the NucliSENS easyMAG extraction system.
Sample type
Sample volume (μL)
Elution volume (μL)
CSF, body fluids, aqueous/vitreous tapping, anterior chamber aspirate
200/100 or ≤50
50 or 30
Plasma
1000/500
25
∗Specimens in VTM
250
55
∗Genital swabs, oral swab, skin swab, vesicle fluid/swab, and respiratory specimens. VTM, viral transport medium.


## 2.3. RealStar®Alpha Herpesvirus PCR

The samples were run in parallel with the in-house multiplex real-time PCR using the RealStar®alpha Herpesvirus PCR Kit 1.0 (altona Diagnostics GmbH, Germany), according to the manufacturer’s instructions. Briefly, PCR was performed using the kit reagents mixed with 5 μL sample template and LightCycler® 480 Instrument II (Roche, Switzerland) with the following PCR conditions: 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and 58°C for 1 min.


## 2.4. In-House Developed Multiplex Real-Time PCR

Primers and probes used for HSV-1, HSV-2, and VZV detection and monitoring PCR inhibition are shown in Table3. A 20 μL reaction mixture contained 5 μL of 4x QuantiNova Multiplex PCR Master Mix (QIAGEN, Germany), 5 μLof nuclease-free water, 400 nM of each primer, 250 nM of each probe, 1 μL of internal control plasmid DNA (1 × 103 copies/μL), and 5 μL of sample template. The in-house multiplex real-time PCR assay was performed by LightCycler® 480 Instrument II (Roche, Switzerland). The PCR conditions consisted of 1 cycle at 95°C for 2 min, followed by 50 cycles at 95°C for 5 s and 60°C for 30 s. Plasmid controls were prepared using the pCRII-TOPO vector (Invitrogen, USA) cloned with target inserts (75 bp UL30 DNA polymerase gene of HSV-1, 117 bp envelope glycoprotein G gene of HSV-2 and 67 bp ORF29 DNA binding protein gene of VZV). Each plasmid stock was diluted in AE buffer, resulting in the concentrations of 1 × 104 copies/reaction and 1 × 102 copies/reaction as high and low positive controls, respectively. To monitor PCR inhibition in the in-house multiplex PCR assay, recombinant plasmid cloned with a 113 bp insert containing EGFP region flanked by primers derived from brome mosaic virus gene sequence of known concentration was diluted in AE buffer to be used as internal control (1 × 103 copies/reaction) [12].Table 3
Primers and probes used for the in-house developed real-time multiplex PCR assay.
Target
Sequence (5′-3′)
Amplicon size
HSV-1
Forward primer
ATCGGCGAGTACTGCATACA
75 bp (UL30 DNA polymerase gene)
Reverse primer
GAGCTCCAGATGGGGCAA
Probe
HEX-ATTCCCTGCTGGTGGGCCA-IABkFQ
HSV-2
Forward primer
ACGCTCTCGTAAATGCTTCC
117 bp (envelope glycoprotein G gene)
Reverse primer
CCACCTCTACCCACAACAGA
Probe
LC610-CGCGGAGACATTCGAGTACCAGATCG-BBQ
VZV
Forward primer
CGAGAACGGTTTGGGTTT
67 bp (ORF29 DNA binding protein gene)
Reverse primer
CGCCGGTCGTCTCAACAG
Probe
FAM-CGCTGCCAAGGGCCTCCTGTT-IABkFQ
Internal control
Forward primer
GTTCACCGATAGACCGCTG
113 bp
Reverse primer
AAGAGCCCGGAATGTCAAGA
Probe
Cy5-ACTACCTGAGCACCCAGTCCGCCCT-BBQ


## 2.5. Analytical Sensitivity, Specificity, and Imprecision

Analytical sensitivity (limit of detection) was determined by evaluating a dilution series of TNA extracted from clinical specimens containing HSV-1 or HSV-2 or VZV. Ten-fold serial dilutions of each recombinant plasmid (HSV-1/HSV-2/VZV) were used to generate standard curves for measuring DNA concentration of original extracts of each virus. Each concentration was tested in 8 replicates for both RealStar® and in-house multiplex real-time PCR assays. Probit analysis was used to calculate the limit of detection (LOD) of the assays. Analytical specificity (cross reactivity) was determined by testing a panel of genomic DNA/RNA extracted from other herpesviruses or other pathogens significant in immunocompromised patients. Imprecision was evaluated by testing different concentrations of TNA extracted from clinical specimens containing each type of virus (in triplicate for each concentration in each run) in two independent runs.


## 3. Results

Performance characteristics of the RealStar®alpha Herpesvirus PCR Kit and the in-house multiplex real-time PCR assay for the detection of HSV-1, HSV-2, and VZV DNA were evaluated. LOD is defined as the concentration of viral DNA that can be detected with a positivity rate of 95% in this study. The LOD of the RealStar® assay was 10, 32, and 100 copies/reaction for HSV-1, HSV-2, and VZV, respectively, while that of the in-house multiplex real-time PCR assay was 24, 63, and 123 copies/reaction for HSV-1, HSV-2 and VZV, respectively (Table 4).Table 4
PCR results used for calculation of analytical sensitivity.
Target
DNA concentration (copies/reaction)
Number of replicates
Number of positives
Hit rates (%)
RealStar®alpha Herpesvirus PCR assay
HSV-1
6.04 × 101
8
8
100
3.02 × 101
8
8
100
1.51 × 101
8
8
100
3.78
8
5
62.5
1
8
1
12.5
No template control
8
0
0
HSV-2
1.76 × 102
8
8
100
8.80 × 101
8
8
100
4.40 × 101
8
8
100
1.10 × 101
8
5
62.5
2.75
8
2
25
No template control
8
0
0
VZV
2.29 × 102
8
8
100
1.15 × 102
8
8
100
5.73 × 101
8
6
75
1.43 × 101
8
2
25
No template control
8
0
0
In-house multiplex PCR assay
HSV-1
6.04 × 101
8
8
100
3.02 × 101
8
8
100
1.51 × 101
8
7
87.5
7.55
8
2
25
3.78
8
2
25
1
8
0
0
No template control
8
0
0
HSV-2
1.76 × 102
8
8
100
8.80 × 101
8
8
100
4.40 × 101
8
7
87.5
2.20 × 101
8
4
50
1.10 × 101
8
3
37.5
2.75
8
0
0
No template control
8
0
0
VZV
2.29 × 102
8
8
100
1.15 × 102
8
7
100
5.73 × 101
8
6
75
2.86 × 101
8
3
37.5
1.43 × 101
8
0
0
No template control
8
0
0The analytical specificity of the RealStar® and in-house multiplex real-time PCR assays was evaluated. Both assays did not show cross reaction with cytomegalovirus, Epstein–Barr virus, human herpesvirus 6, 7, and 8, BK virus, JC virus, hepatitis B and C viruses, parvovirus B19, and human enterovirus. The HSV-1, HSV-2, and VZV primer/probe combinations within both multiplex PCR assays were target specific; both RealStar® and in-house assays are able to distinguish between HSV-1, HSV-2, and VZV.In the replication experiment, three replicates of each concentration of TNA extracted from clinical specimens containing each viral target (HSV-1, HSV-2 or VZV) were tested to evaluate the intra- and interassay variations. The reproducibility of the Cp values for each target was satisfactory; total imprecision (% CV) values ranged from 0.80% to 1.94% for the RealStar® assay and 0.33% to 2.50% for the in-house multiplex PCR assay (Table5).Table 5
Imprecision testing of the RealStar® and in-house multiplex real-time PCR assays using HSV-1, HSV-2, and VZV extracts.
DNA concentration (copies/reaction)
Intra-assay
Interassay
No. of positive replicates
Mean Cp ± SD (% coefficient of variation)
Mean Cp ± SD (% coefficient of variation)
RealStar®alpha Herpesvirus PCR assay
HSV-1
6.04 × 102
3
31.41 ± 0.12 (0.38)
31.38 ± 0.26 (0.84)
6.04 × 101
3
33.99 ± 0.32 (0.93)
34.16 ± 0.36 (1.06)
HSV-2
1.76 × 103
3
30.90 ± 0.08 (0.26)
30.71 ± 0.26 (0.80)
1.76 × 102
3
32.98 ± 0.08 (0.25)
33.37 ± 0.44 (1.30)
VZV
2.29 × 103
3
31.54 ± 0.13 (0.41)
31.84 ± 0.35 (1.11)
2.29 × 102
3
34.42 ± 0.39 (1.12)
34.91 ± 0.68 (1.94)
In-house multiplex PCR
HSV-1
6.04 × 103
3
30.79 ± 0.12 (0.39)
30.80 ± 0.10 (0.33)
6.04 × 102
3
34.09 ± 0.15 (0.45)
34.09 ± 0.18 (0.52)
6.04 × 101
3
37.46 ± 0.85 (2.28)
37.84 ± 0.85 (2.26)
HSV-2
1.76 × 104
3
30.57 ± 0.16 (0.52)
30.39 ± 0.23 (0.76)
1.76 × 103
3
34.65 ± 0.21 (0.61)
34.20 ± 0.51 (1.50)
1.76 × 102
3
37.79 ± 0.57 (1.52)
37.63 ± 0.56 (1.50)
VZV
2.29 × 104
3
30.64 ± 0.06 (0.18)
30.11 ± 0.58 (1.91)
2.29 × 103
3
33.87 ± 0.36 (1.05)
33.14 ± 0.83 (2.50)
2.29 × 102
3
36.09 ± 0.45 (1.25)
36.13 ± 0.40 (1.11)Among the 153 clinical specimens and 15 samples for EQA subjected to HSV-1, HSV-2, and VZV detection, 60 were positive (31 HSV-1, 14 HSV-2, and 15 VZV) and 108 were negative by both RealStar® and in-house multiplex real-time PCR assays (Supplementary TableS1). No PCR inhibition was observed in each reaction for both assays. Using the in-house multiplex real-time PCR assay as the reference method, the sensitivity and specificity of the RealStar® assay were 100% (Table 6). There was a good agreement in performance of the RealStar® assay compared to the in-house multiplex assay demonstrating strong correlation with a coefficient of determination (R2) of 0.99 for each target (Figure 1). For the EQA samples evaluation, both RealStar® and in-house multiplex real-time PCR assays could give 100% correct results for the proficiency testing samples from CAP and QCMD (Supplementary Table S1).Table 6
Diagnostic performance of the RealStar® assay compared to the in-house HSV and VZV multiplex real-time PCR assay.
In-house multiplex real-time PCR assay
Positive
Negative
Total
Sensitivity % (95% CI)
Specificity % (95% CI)
RealStar® assay
Positive
60
0
60
100 (94.0–100)
100 (96.6–100)
Negative
0
108
108
Total
60
108
168Figure 1
Correlation of the Cp values of the samples found positive for (a) HSV-1, (b) HSV-2, and (c) VZV by the RealStar® and in-house HSV and VZV multiplex real-time PCR assays.
(a)
(b)
(c)


## 4. Discussion

In recent years, several FDA-approved or CE-marked in vitro diagnostic (IVD) commercial PCR kits have been launched for the detection of HSV and VZV in clinical specimens, such as Focus Diagnostics (Cypress, CA), EraGen Biosciences, Inc. (Madison, WI), and Lyra Direct HSV 1 + 2/VZV assay (Quidel Corporation, CA), and their diagnostic performances have been well studied [13–15]. At the time of writing, another CE-IVD kit, RealStar® alpha Herpesvirus PCR Kit, has been used for resolving discordant results [11], but its performance characteristics have not been well evaluated. In this study, using a variety of specimens derived from patients and EQA samples, we were able to demonstrate that the diagnostic performance of the RealStar® alpha Herpesvirus PCR assay was equivalent to that of our in-house multiplex real-time PCR assay. Furthermore, we showed that the RealStar® alpha Herpesvirus PCR assay was noninferior to the in-house multiplex PCR assay in terms of analytical sensitivity. Reproducibility of the cycle threshold (Cp) values for each viral target was satisfactory with the intra-and interassay coefficient of variation values below 5% for these two assays. Cp values of both assays showed excellent correlation. The assays also performed well in proficiency testing samples from two EQA service providers. According to the package insert, the RealStar® alpha Herpesvirus PCR assay has been designed for use with several amplification instruments but not with LightCycler® 480 Instrument II. In the present study, the RealStar® assay was validated to be used with LC480 PCR system based on our evaluation results. Since LC480 PCR system provides 384-well format for high-throughput real-time PCR, it would be advantageous for reference laboratories that process large number of specimens every day. In a study on in-house quadruplex real-time PCR for rapid detection of human alpha herpesviruses, Krumbholz et al. have evaluated the matrix effect and effects of multiple infections [16], and these data can underline results on assay performance. Thus, studying these two effects is worthy to be included in the future studies, because this can make the evaluation of the assays more complete.Compared to conventional PCR, real-time PCR minimizes the risk of amplicons carryover contamination, saves time, and enables estimation of viral load in clinical specimens. By combining multiple reaction targets in a single vessel, multiplex real-time PCR assays enable the laboratory to improve the turnaround time and optimize the manpower allocation [17]. Such multiplex testing facilitates diagnostic test panel-based reporting, which is advantageous when multiple pathogens can produce a similar clinical presentation. The RealStar® assay takes around 130 min; starting with the total nucleic acid extraction until the report of results, the time is a bit longer than the in-house assay which takes around 100 min. While commercial kits are easier to implement, developing tests in-house further enables the laboratory to significantly save on reagent costs. Our in-house multiplex real-time PCR assay costs US$ 2 per reaction compared to US$ 17.5 per reaction for the RealStar® alpha Herpesvirus PCR Kit.The potential drawback of multiplex real-time PCR is the potential loss of sensitivity due to combination of multiple primers and probes (including internal control) in a single reaction. We did not observe this phenomenon with either the in-house multiplex real-time PCR or commercial kit when compared to in-house conventional monoplex nested PCR assay (data not shown). Another disadvantage is a loss in testing flexibility, i.e., laboratories are forced to test for VZV even when the clinical presentation is highly suggestive of HSV and vice versa. However, given the overlapping presentations and possibility of HSV/VZV coinfections, detection of both targets simultaneously may enable more precise diagnosis than selective PCR testing in some cases.


## 5. Conclusions

RealStar®alpha Herpesvirus PCR assay is highly sensitive, specific, and reliable for the detection and differentiation of HSV-1, HSV-2, and VZV in a variety of human clinical specimens.



---

*Source: 5715180-2019-10-09.xml*